Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies
Individuals with longer-standing T1D and low levels of C-peptide at baseline were more likely to discontinue adjunctive liraglutide treatment due to AEs/lack of tolerance than individuals with residual insulin production. Lower BMI predicted a greater likelihood of non-completion for the included participants, regardless of treatment. These new findings may be relevant for clinical practice.
Authors
- Jerry Richard Greenfield (ORCID: https://orcid.org/0000-0002-0866-0973)
- Jennifer Snaith (ORCID: https://orcid.org/0000-0001-8559-8387)
- Lars Bardtrum
- Viral N. Shah (ORCID: https://orcid.org/0000-0002-3827-7107)
- Erik Christiansen (ORCID: https://orcid.org/0000-0003-3562-9506)
- Rikke Mette Agesen (ORCID: https://orcid.org/0000-0002-7649-7928)
Institutions
- Garvan Institute of Medical Research (AU)
- Novo Nordisk (Denmark) (DK)
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- St Vincent's Health (AU)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Journal of Diabetes Science and Technology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1177/19322968241305647
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.50
Funders
- Novo Nordisk